Cargando...
Fidaxomicin for the treatment of Clostridioides difficile in children
Fidaxomicin is an oral narrow-spectrum novel 18-membered macrocyclic antibiotic that was initially approved in 2011 by the US FDA for the treatment of Clostridioides difficile infections (CDI) in adults. In February 2020, the FDA approved fidaxomicin for the treatment of CDI in children age >6 mo...
Gardado en:
| Publicado en: | Future Microbiol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Future Medicine Ltd
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8097504/ https://ncbi.nlm.nih.gov/pubmed/32715754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fmb-2020-0104 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|